EP1146904A4 - Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv - Google Patents

Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv

Info

Publication number
EP1146904A4
EP1146904A4 EP00905949A EP00905949A EP1146904A4 EP 1146904 A4 EP1146904 A4 EP 1146904A4 EP 00905949 A EP00905949 A EP 00905949A EP 00905949 A EP00905949 A EP 00905949A EP 1146904 A4 EP1146904 A4 EP 1146904A4
Authority
EP
European Patent Office
Prior art keywords
autovaccination
hydroxyurea
induce
reverse transcriptase
transcriptase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00905949A
Other languages
German (de)
French (fr)
Other versions
EP1146904A1 (en
Inventor
Franco Lori
Juliana Lisziewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/493,769 external-priority patent/US20030095988A1/en
Application filed by Individual filed Critical Individual
Publication of EP1146904A1 publication Critical patent/EP1146904A1/en
Publication of EP1146904A4 publication Critical patent/EP1146904A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00905949A 1999-02-03 2000-02-02 Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv Withdrawn EP1146904A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24375399A 1999-02-03 1999-02-03
US243753 1999-02-03
US493769 2000-01-28
US09/493,769 US20030095988A1 (en) 2000-01-28 2000-01-28 Method of inducing autovaccination against HIV infection using structured treatment interruptions
PCT/US2000/002754 WO2000045844A1 (en) 1999-02-03 2000-02-02 Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv

Publications (2)

Publication Number Publication Date
EP1146904A1 EP1146904A1 (en) 2001-10-24
EP1146904A4 true EP1146904A4 (en) 2004-09-15

Family

ID=26936052

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00905949A Withdrawn EP1146904A4 (en) 1999-02-03 2000-02-02 Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv

Country Status (3)

Country Link
EP (1) EP1146904A4 (en)
AU (1) AU2753700A (en)
WO (1) WO2000045844A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095988A1 (en) * 2000-01-28 2003-05-22 Julianna Lisziewicz Method of inducing autovaccination against HIV infection using structured treatment interruptions
FR2821556B1 (en) * 2001-03-02 2003-04-25 Aventis Pasteur USE OF LIPOPEPTIDES FOR IMMUNOTHERAPY OF HIV + SUBJECTS
WO2002058726A1 (en) * 2001-01-26 2002-08-01 The Immune Response Corporation Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027590A1 (en) * 1993-05-21 1994-12-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
WO1996022777A1 (en) * 1995-01-25 1996-08-01 Compagnie De Developpement Aguettant Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US6114312A (en) * 1997-03-07 2000-09-05 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027590A1 (en) * 1993-05-21 1994-12-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
WO1996022777A1 (en) * 1995-01-25 1996-08-01 Compagnie De Developpement Aguettant Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0045844A1 *

Also Published As

Publication number Publication date
AU2753700A (en) 2000-08-25
EP1146904A1 (en) 2001-10-24
WO2000045844A1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
SG80631A1 (en) Inhibitors of hiv reverse transcriptase
AU6202900A (en) Restoration of a computer to a previous state
IL149219A0 (en) Tricyclic compounds useful as hiv reverse transcriptase inhibitors
HK1080852A1 (en) 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
AU1046895A (en) New quinazolines as inhibitors of hiv reverse transcriptase
AR009356A1 (en) COMPOUND OF 1-4 HETEROCICLICO, METALOPROTEASE INHIBITOR AND ITS USE TO PREPARE A PHARMACEUTICAL COMPOSITION AND TO PREVENT OR TREAT A DISEASE ASSOCIATED WITH METALO PROTEASE ACTIVITY AND CAQUEXIA
PL310410A1 (en) Inhibitors of reverse hiv transcriptase
AU1420402A (en) Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
ID28436A (en) TOOL FOR USE TO APPEAR
EP1146904A4 (en) Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv
PL340239A1 (en) Corrosion inhibitor to be added to a gas treatment colution
HUT71401A (en) New quinazolines as inhibitors of hiv reverse transcriptase
AU2001270193A1 (en) Pharmaceutical composition containing psyllium fiber and a lipase inhibitor
HK1053334A1 (en) Phytomics: a genomic-based approach to herbal compositions
AU2001249161A1 (en) Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
NO20030248L (en) Tricyclic pyridone compounds useful as HIV reverse transcriptase inhibitors
ID24940A (en) THE USE OF THE TOLLIDES TO PREVENT AROMIC TROMBOTIC COMPLICATIONS OF ATEROSCLEROSIS
ZA98975B (en) Melanins with improved ability to inhibit hiv replication
AU2002218610A1 (en) Improvements in or relating to a tampon
AU2001247412A1 (en) Conversion of hydrocarbon-contaminated particulate soil and/or rock to fertile soil
AU2003277268A8 (en) Therapeutic aptamers having binding specificity to gp41 of hiv
AU2119695A (en) Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
CA101611S (en) Paper napkin
AU2002237251A1 (en) A pharmaceutical composition containing benzopyrano-oxopyrimidotetrahydrothiazine and its use in the treatment of hiv

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010809

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010809;LT PAYMENT 20010809;LV PAYMENT 20010809;MK PAYMENT 20010809;RO PAYMENT 20010809;SI PAYMENT 20010809

A4 Supplementary search report drawn up and despatched

Effective date: 20040729

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040901